Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 82-91

  Yamauchi, Takahiro ^a   Ogawa, Masami ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Preclinical Research Department   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLGUANINE O 6; CADMIUM CHLORIDE; CARMUSTINE; GUANINE ALKYLTRANSFERASE; GUANINE DERIVATIVE; METHOXYAMINE; NIMUSTINE; PROTEIN MLH1; PROTEIN MSH2; PURINE DERIVATIVE; TEMOZOLOMIDE; TRANSFERASE;

ALKYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; EXCISION REPAIR; HUMAN; HUMAN CELL; IC 50; MISMATCH REPAIR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CADMIUM CHLORIDE; CARMUSTINE; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DACARBAZINE; DNA MISMATCH REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GUANINE; HUMANS; HYDROXYLAMINES; NIMUSTINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 45749156773     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041988     Document Type: Article

References (38)

1. Aquilina G, Ceccotti S, Martinelli S, Hampson R, and Bignami M (1998) N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res 58:135-141.
2. Banerjee S and Flores-Rozas H (2005) Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2-MSH6 complex. Nucleic Acids Res 33:1410-1419.
3. Barvaux VA, Ranson M, Brown R, McElhinney RS, McMurry TB, and Margison GP (2004) Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther 3:123-127.
4. 6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11:2747-2755.
5. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SM, Xu W, Minden MD (2007) A phase II study of temozolomide therapy for poor-risk patients aged >or= 60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 21:821-824.
6. Chaney SG and Sancar A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88:1346-1360.
7. Clark AB and Kunkel TA (2004) Cadmium inhibits the functions of eukaryotic MutS complexes. J Biol Chem 279:53903-53906.
8. Drabløs F, Feyzi E, Aas PA, Vaagbø CB, Kavli B, Bratlie MS, Peña-Diaz J, Otterlei M, Slupphaug G, and Krokan HE (2004) Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 3:1389-1407.
9. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, and Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354.
10. Fine HA, Dear KB, Loeffler JS, Black PM, and Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597.
11. Fink D, Aebi S, and Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6.
12. Fiumicino S, Martinelli S, Colussi C, Aquilina G, Leonetti C, Crescenzi M, and Bignami M (2000) Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int J Cancer 85:590-596.
13. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol 25:4922-4928.
14. Jin YH, Clark AB, Slebos RJ, Al-Refai H, Taylor JA, Kunkel TA, Resnick MA, Gordenin DA (2003) Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat Genet 34:326-329.
15. Kolodner RD and Marsischky GT (1999) Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9:89-96.
16. Liu L, Taverna P, Whitacre CM, Chatterjee S, and Gerson SL (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5:2908-2917.
17. Lützen A, Liberti SE, and Rasmussen LJ (2004) Cadmium inhibits human DNA mismatch repair in vivo. Biochem Biophys Res Commun 321:21-25.
18. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Galo JM (2002) Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozlomide-acquired resistance. Biochem Pharmacol 63:1219-1228.
19. Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P, Heinimann K, Bartosova Z, Nyström-Lahti M, and Jiricny J (2001) Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci U S A 98:7164-7169.
20. Mason WP and Cairncross JG (2005) Drug Insight: temozolomide as a treatment for malignant glioma - impact of a recent trial. Nat Clin Pract Neurol 1:88-95.
21. Matheson EC and Hall AG (2003) Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis 24:31-38.
22. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, and Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61.
23. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, and Aloyz R (2001) Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7:454-461.
24. 6-alkylguanine- DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304:661-668.
25. Plosky B, Samson L, Engelward BP, Gold B, Schlaen B, Millas T, Magnotti M, Schor J, and Scicchitano DA (2002) Base excision repair and nucleotide excision repair contribute to the removal of N-methylpurines from active genes. DNA Repair 1:683-696.
26. Reddy MC and Vasquez KM (2005) Repair of genome destabilizing lesions. Radiat Res 164:345-356.
27. Rinne M, Caldwell D, and Kelley MR (2004) Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther 3:955-967.
28. Sansom OJ, Toft NJ, Winton DJ, and Clarke AR (2001) Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner. Oncogene 20:3580-3584.
29. Stupp R, Gander M, Leyvraz S, and Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552-560.
30. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2006) Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180.
31. Taverna P, Liu L, Hanson AJ, Monks A, and Gerson SL (2000) Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46:507-516.
32. Wiencke JK and Wiemels L (1995) Genotoxicity of 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res 339:91-119.
33. Wu Q, Christensen LA, Legerski RJ, and Vasquez KM (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 6:551-557.
34. Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, and Ueda T (2007) Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol 85:108-115.
35. Yamauchi T, Nowak BJ, Keating MJ, and Plunkett W (2001) DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4- hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589.
36. Yamauchi T, Keating MJ, and Plunkett W (2002) UCN-01 inhibits DNA repair and induces cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 1:287-294.
37. Yamauchi T, Kawai Y, and Ueda T (2003) Enhanced DNA excision repair in CCRFCEM cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea, quantitated using the single cell gel electrophoresis (Comet) assay. Biochem Pharmacol 66:939-946.
38. 6-methylguanine adducts. Mol Cell 22:501-510.